東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Cancer epigenetics: Linking basic me...

Han, Han.

FindBook

Google Book

Amazon

博客來

Cancer epigenetics: Linking basic mechanisms to therapy.

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Cancer epigenetics: Linking basic mechanisms to therapy./
作者:	Han, Han.
面頁冊數:	149 p.
附註:	Source: Dissertation Abstracts International, Volume: 74-10(E), Section: B.
Contained By:	Dissertation Abstracts International74-10B(E).
標題:	Biology, Molecular. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3563875
ISBN:	9781303123887

Cancer epigenetics: Linking basic mechanisms to therapy.
Han, Han.

Cancer epigenetics: Linking basic mechanisms to therapy. - 149 p.

Source: Dissertation Abstracts International, Volume: 74-10(E), Section: B.

Thesis (Ph.D.)--University of Southern California, 2013.

Due to the technology revolution in epigenetic profiling, the number of genes that contain epigenetic aberrations in disease is growing, emphasizing the critical role of epigenetics in disease states. The reversibility of epigenetic abnormalities upon pharmacological interventions has spurred interest in developing epigenetic therapy with the primary goal of restoring the expression of aberrantly silenced genes. The focus of this thesis was twofold: to elucidate the role of DNA methylation occurring at non-CpG island promoters and investigate mechanisms involved in therapeutic efficacy of a DNA methyltransferase inhibitor, 5-Aza-2'-deoxycytidine.

ISBN: 9781303123887Subjects--Topical Terms:

1017719
Biology, Molecular.

Cancer epigenetics: Linking basic mechanisms to therapy.
LDR:03512nam a2200301 4500 001 1965551
005 20141030134120.5
008 150210s2013 ||||||||||||||||| ||eng d
020 $a 9781303123887
035 $a (MiAaPQ)AAI3563875
035 $a AAI3563875
040 $a MiAaPQ $c MiAaPQ
100 1 $a Han, Han. $3 1033727
245 1 0 $a Cancer epigenetics: Linking basic mechanisms to therapy.
300 $a 149 p.
500 $a Source: Dissertation Abstracts International, Volume: 74-10(E), Section: B.
500 $a Adviser: Peter A. Jones.
502 $a Thesis (Ph.D.)--University of Southern California, 2013.
520 $a Due to the technology revolution in epigenetic profiling, the number of genes that contain epigenetic aberrations in disease is growing, emphasizing the critical role of epigenetics in disease states. The reversibility of epigenetic abnormalities upon pharmacological interventions has spurred interest in developing epigenetic therapy with the primary goal of restoring the expression of aberrantly silenced genes. The focus of this thesis was twofold: to elucidate the role of DNA methylation occurring at non-CpG island promoters and investigate mechanisms involved in therapeutic efficacy of a DNA methyltransferase inhibitor, 5-Aza-2'-deoxycytidine.
520 $a In the field of epigenetics, the significance of CpG island methylation in both normal and disease states, especially in cancer, has been well elucidated. However, the importance of DNA methylation occurring at non-CpG island promoters and its potential role in tumorigenesis are still controversial. Using LAMB3 and RUNX3 as examples, I have shown that DNA methylation directly silences genes containing non-CpGI promoters and their epigenetic signatures are almost identical to CpG island promoters, suggesting aberrant methylation patterns of non-CpG island promoters may also contribute to tumorigenesis and should therefore be included in analyses of cancer epigenetics.
520 $a The clinical efficacies of DNA methyltransferase inhibitors are irrefutable; however, mechanisms involved in therapeutic efficacy of these inhibitors are not completely understood. By investigating genome-wide changes in DNA methylation and gene expression at various time points after transient exposure to 5-Aza-CdR, I revealed that different genomic regions have different rate of remethylation upon drug withdrawal. In general, promoters remethylate much slower than gene bodies, resulting in sustained DNA demethylation and subsequent gene reactivation, which may potentially responsible for the less tumorigenic phenotype of cancer cells produced by transient exposure to 5-Aza-CdR. Elucidating the therapeutic efficacy of 5-Aza-CdR helps pave the way for developing combinatorial therapies to target multiple aberrant epigenetic modifiers. I also demonstrated the efficacy of combining 5-Aza-CdR with clorgyline, a lysine specific demethylase inhibitor, in enhancing the degree and prolonging the duration of gene reactivation. Taken together, this thesis presents the role of non-CpG island methylation and the therapeutic mechanism of 5-Aza-CdR, thus aiding in developing new epigenetic therapies, extending the application of and improving the efficacies of current therapies.
590 $a School code: 0208.
650 4 $a Biology, Molecular. $3 1017719
650 4 $a Health Sciences, Pharmacy. $3 1017737
690 $a 0307
690 $a 0572
710 2 $a University of Southern California. $b Pharmaceutical Sciences. $3 2102227
773 0 $t Dissertation Abstracts International $g 74-10B(E).
790 $a 0208
791 $a Ph.D.
792 $a 2013
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3563875